+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hematological Drugs Market Research Reports

Factor Xa inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Factor Xa inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Factor IIa (Thrombin) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Factor IIa (Thrombin) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
JAKAFI Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

JAKAFI Emerging Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
EMPAVELI Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

EMPAVELI Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
From
From
Sickle Cell Disease - Epidemiology Forecast - 2032 - Product Thumbnail Image

Sickle Cell Disease - Epidemiology Forecast - 2032

  • Report
  • August 2023
  • 80 Pages
  • Global
From
Anemia in Chronic Kidney - Pipeline Insight, 2024 - Product Thumbnail Image

Anemia in Chronic Kidney - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Sickle Cell Disease (SCD) - Pipeline Insight, 2024 - Product Thumbnail Image

Sickle Cell Disease (SCD) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 170 Pages
  • Global
From
Behçet disease - Pipeline Insight, 2024 - Product Thumbnail Image

Behçet disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Factor VIII Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Factor VIII Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Plasminogen Activator Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Plasminogen Activator Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Platelet Derived Growth Factor Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Platelet Derived Growth Factor Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
P2Y12 Platelet ADP Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

P2Y12 Platelet ADP Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Factor VIIa Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Factor VIIa Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Plasminogen Activator Inhibitor-1 (PAI-1) - Pipeline Insight, 2024 - Product Thumbnail Image

Plasminogen Activator Inhibitor-1 (PAI-1) - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Plasmin Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Plasmin Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Factor IX A Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Factor IX A Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Factor II (Prothrombin) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Factor II (Prothrombin) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Hematological Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat hematological diseases. These diseases include anemia, leukemia, lymphoma, and other blood disorders. Hematological drugs are used to treat a variety of conditions, including cancer, autoimmune diseases, and blood disorders. The hematological drugs market is composed of a variety of companies, including large pharmaceutical companies, biotechnology companies, and specialty drug companies. These companies develop and produce drugs to treat hematological diseases, as well as other conditions. Some of the major players in the hematological drugs market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more